[go: up one dir, main page]

DE60334830D1 - Furin-hemmer zur behandlung von fibrose und narbenbildung - Google Patents

Furin-hemmer zur behandlung von fibrose und narbenbildung

Info

Publication number
DE60334830D1
DE60334830D1 DE60334830T DE60334830T DE60334830D1 DE 60334830 D1 DE60334830 D1 DE 60334830D1 DE 60334830 T DE60334830 T DE 60334830T DE 60334830 T DE60334830 T DE 60334830T DE 60334830 D1 DE60334830 D1 DE 60334830D1
Authority
DE
Germany
Prior art keywords
treatment
fibrosis
scarcing
hemmer
furin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334830T
Other languages
English (en)
Inventor
Mark W J Ferguson
G Brunner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DE60334830D1 publication Critical patent/DE60334830D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60334830T 2002-07-24 2003-07-23 Furin-hemmer zur behandlung von fibrose und narbenbildung Expired - Lifetime DE60334830D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0217136.1A GB0217136D0 (en) 2002-07-24 2002-07-24 Wound healing & treatment of fibrosis
PCT/GB2003/003159 WO2004009113A1 (en) 2002-07-24 2003-07-23 Use of convertase inhibitors in the treatment of fibrosis and scarring

Publications (1)

Publication Number Publication Date
DE60334830D1 true DE60334830D1 (de) 2010-12-16

Family

ID=9941004

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334830T Expired - Lifetime DE60334830D1 (de) 2002-07-24 2003-07-23 Furin-hemmer zur behandlung von fibrose und narbenbildung

Country Status (11)

Country Link
US (2) US7700562B2 (de)
EP (1) EP1556080B1 (de)
JP (1) JP4630661B2 (de)
AT (1) ATE486609T1 (de)
AU (1) AU2003254473B2 (de)
CA (1) CA2492331A1 (de)
DE (1) DE60334830D1 (de)
DK (1) DK1556080T3 (de)
ES (1) ES2355094T3 (de)
GB (1) GB0217136D0 (de)
WO (1) WO2004009113A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663300A1 (de) * 2003-09-16 2006-06-07 Pharmacia Corporation Hemmer von pace4 zur behandlung von arthritis
WO2005037150A1 (en) * 2003-10-16 2005-04-28 Osteotech, Inc. System and method for flexible correction of bony motion segment
WO2008066707A2 (en) * 2006-11-29 2008-06-05 Dana-Farber Cancer Institute Targeting prohormone convertase enzymes to suppress pomc-msh processing to induce skin lightening
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
WO2010003231A1 (en) * 2008-07-11 2010-01-14 Socpra-Sciences Et Génie S.E.C. Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents
CA2819810A1 (en) * 2010-12-06 2012-06-14 The University Of British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
JP6472608B2 (ja) 2014-05-21 2019-02-20 ソマール株式会社 Ｎ−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム
WO2017141032A1 (en) * 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders
FR3110345B1 (fr) 2020-05-21 2024-03-29 Agence Francaise Pour Le Dev D’Al Ula Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356595A1 (de) 1988-09-01 1990-03-07 Merrell Dow Pharmaceuticals Inc. Peptidase-Hemmer
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5439824A (en) * 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II
GB9314350D0 (en) * 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives
US5972335A (en) * 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
GB2324960A (en) * 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
EP1140041A2 (de) * 1999-01-05 2001-10-10 University of Utah Research Foundation Verfahren zur behandlung von mit der akkumulation der extrazellulären matrix-assozierten störungen
US6262020B1 (en) 2000-02-15 2001-07-17 Alphamed Pharmaceuticals Corp. Topical wound therapeutic compositions
CA2312109A1 (en) * 2000-06-23 2001-12-23 Universite De Sherbrooke Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides

Also Published As

Publication number Publication date
US20110059896A1 (en) 2011-03-10
EP1556080B1 (de) 2010-11-03
ATE486609T1 (de) 2010-11-15
CA2492331A1 (en) 2004-01-29
ES2355094T3 (es) 2011-03-22
WO2004009113A1 (en) 2004-01-29
US20060052309A1 (en) 2006-03-09
AU2003254473B2 (en) 2008-05-01
JP4630661B2 (ja) 2011-02-09
HK1073438A1 (en) 2005-10-07
US7700562B2 (en) 2010-04-20
DK1556080T3 (da) 2011-01-31
AU2003254473A1 (en) 2004-02-09
GB0217136D0 (en) 2002-09-04
JP2005535674A (ja) 2005-11-24
EP1556080A1 (de) 2005-07-27

Similar Documents

Publication Publication Date Title
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
MXPA04001033A (es) Compuesto de sanado para heridas y anti-cancer.
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
ATE473753T1 (de) Verwendung von botulinum toxin zur behandlung von post-operative schmerzen
ATE414556T1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60235545D1 (de) Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen
DE60334830D1 (de) Furin-hemmer zur behandlung von fibrose und narbenbildung
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE256461T1 (de) Benutzung von comt-inhibitoren als analgetika
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE60044584D1 (de) Protease from lucilia sericata und deren verwendung zur wundheilung
ATE264101T1 (de) Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE270895T1 (de) Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen